Hoffmann-la Roche Inc.

Madrigal Pharmaceuticals, Inc.

Via Pharmaceuticals, Inc.

F. Hoffmann-la Roche Ag

Jenny Tan

Fariborz Firooznia

Adrian Wai-Hing Cheung

Yimin Qian

Matthew Michael Hamilton

Sung-Sau So

David Robert Bolin

Weiya Yun

Yan Lou

Francisco Javier Lopez-Tapia

Paul Gillespie

Achyutharao Sidduri

Timothy D Owens

Peter Michael Wovkulich

Roland Joseph Billedeau

Eric Mertz

Christine E Brotherton-Pleiss

Kevin Richard Guertin

Kshitij Chhabilbhai Thakkar

Buelent Kocer

Tai-An Lin

Steven Joseph Berthel

Saul Jaime-Figueroa

Stephen Deems Gabriel

Lee Apostle McDermott

Lida Qi

Xiaochun Han

Nicholas Marcopulos

Lucja Orzechowski

Ramona Hilgenkamp

Jefferson Wright Tilley

Ramakanth Sarabu

Robert Alan Goodnow, Jr

Nancy-Ellen Haynes

John A Brinkman

Stuart Hayden

Joseph Anthony Bilotta

Jagdish Kumar Racha

Lee Aopstle McDermott

Christine M Lukacs-Lesburg

This application discloses 6-(2-Hydroxymethyl-phenyl)-2-methyl-2H-pyridazin-3-one derivatives according to generic Formula I: wherein, variables X, R, and Y, are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation, such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.

Inhibitors of bruton's tyrosine kinase

The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula I: wherein the variables are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.

Aminomethyl quinolone compounds

The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein R-Rare defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

Substituted aminotetralines

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

Diacylglycerol acyltransferase inhibitors

The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein X, Q, and R-Rare defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

Naphthylacetic acids

There are presented compounds of the formula  or a pharmaceutically acceptable salt thereof, which are active adenosine A2B receptor antagonists and useful in the treatment of diabetes, diabetic retinopathy, asthma and diarrhea.

Substituted thiazolo[5,4-d]pyrimidine urea derivatives

Growing community of inventors

New Providence, NJ, United States of America

Jenny Tan